Estrogen Treatment in Acromegalic Women

Université de Montréal30 enrolled

Overview

Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.

This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Acromegaly

Interventions

AlesseDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women 18 years and older treated with somatostatin analogs * Active acromegaly Exclusion Criteria: * Cardiovascular or cerebrovascular disease * Thrombophlebitis or thromboembolism * Breast cancer * Non-controlled arterial hypertension * Smoking * Pregnancy or lactation

Locations (1)

CHUM - Notre-Dame Hospital

Montreal, Quebec, Canada

RECRUITING

Central Contacts

Omar SERRI, MD

CONTACT

514-890-8000 omar.serri@umontreal.ca

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.